<DOC>
	<DOCNO>NCT01757457</DOCNO>
	<brief_summary>Intracoronary abciximab administration primary percutaneous coronary intervention ( pPCI ) could offer clinical advantage intravenous route . The aim study ass whether abciximab administration route could influence anti-inflammatory effect . 87 consecutive STEMI patient candidate pPCI randomize receive intracoronary intravenous abciximab bolus . The primary endpoint extent inflammation , measure C-reactive protein ( CRP ) , VCAM-1 ICAM-1 level .</brief_summary>
	<brief_title>Anti-inflammatory Effects Intracoronary Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention</brief_title>
	<detailed_description>BACKGROUND : intracoronary abciximab administration primary percutaneous coronary intervention ( pPCI ) could offer clinical advantage intravenous route . Besides antiplatelet effect , abciximab modulate inflammation via cross-reactivity GPIIb/IIIa , avb3 , aMb2 receptor . The aim study ass whether abciximab administration route could influence anti-inflammatory effect . METHODS : 87 consecutive STEMI patient candidate pPCI randomize receive intracoronary ( Group A , 47 patient ) intravenous ( Group B , 42 patient ) abciximab bolus . The primary endpoint extent inflammation , measure C-reactive protein ( CRP ) , VCAM-1 ICAM-1 level .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>presence STEMI accord universal definition myocardial infarction ( 7 ) ; hospital admission within 12 hour symptom onset ; successful treatment primary PCI , define procedure achieve infarctrelated artery ( IRA ) patency le 10 % residual coronary stenosis base visual estimation . age &gt; 90 year ; cardiogenic shock admission ; leave main IRA ; saphenous vein graft IRA ; previous PCI last 6 month ; severe renal impairment ( eGFR &lt; 30ml/min ) dialysis treatment ; thrombolytic drug administration last 30 day admission ; know malignancy diagnose less 5 year admission ; know active infectious , coagulative systemic inflammatory disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>inflammation</keyword>
	<keyword>thrombosis</keyword>
	<keyword>platelet</keyword>
	<keyword>adhesion molecule</keyword>
	<keyword>endothelium</keyword>
</DOC>